---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342334"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-08-10T20:05:19+00:00"
generated_at: "2026-08-10T20:09:52.393671+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete

## Summary
- Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).
- Cash, equivalents, and marketable securities totaled $461.1M as of June 30, 2026.
- Completed enrollment in Phase 3 OPERA-01 (palazestrant monotherapy); top-line data expected Q1 2027.
- Announced Bayer collaboration to study OP-3136 plus darolutamide in mCRPC; enrollment starts Q4 2026.
- Presented initial Phase 1 data for OP-3136 at ASCO 2026 showing tolerability and anti-tumor activity.

## SEC filing metadata
- accession: 0001193125-26-342334
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-08-10T20:05:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/0001193125-26-342334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342334
- JSON: https://secwatch.observer/filing/0001193125-26-342334.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.